Choose Your Country or Region

Halobetasol Propionate

Name: Halobetasol Propionate
Brand: Selleck Chemicals
SKU: S4089
Rating: 5 (1 reviews)

Synonyms: BMY-30056, CGP-14458,Ulobetasol propionate

Catalog No.S4089 Purity:99.92%

Halobetasol Propionate (BMY-30056, CGP-14458,Ulobetasol propionate) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis.

Halobetasol Propionate Chemical Structure

CAS No. 66852-54-8

Purity & Quality Control

Batch: S408901 DMSO]97 mg/mL]false]Ethanol]38 mg/mL]false]Water]Insoluble]false Purity: 99.92%

99.92

Halobetasol Propionate Related Products

Related Targets	PLA2 PLC PLD LYPLA1 Smase	Click to Expand
Related Products	U73122 GW4869 Varespladib (LY315920) Tanshinone I Darapladib Quinacrine 2HCl CAY10593 (VU0155069) m-3M3FBS Melittin Trigonelline	Click to Expand
Related Compound Libraries	Metabolism Compound Library Anti-cancer Metabolism Compound Library Glutamine Metabolism Compound Library Carbohydrate Metabolism Compound Library Lipid Metabolism Compound Library	Click to Expand

Signaling Pathway

Phospholipase (e.g. PLA) Signaling Pathway

Biological Activity

Description

Halobetasol Propionate (BMY-30056, CGP-14458,Ulobetasol propionate) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis.

Targets

PLA2 ^[1]

In vitro
In vitro	Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.^[1]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT03988439	Recruiting	Psoriasis	Bausch Health Americas Inc.	March 24 2021	Phase 4
NCT03987763	Recruiting	Psoriasis	Bausch Health Americas Inc.	October 22 2019	Phase 4

References

[1] Mohandas S, et al. Indian J Dermatol Venereol Leprol, 2009, 75(2), 186-187.

Chemical Information & Solubility

Molecular Weight	484.96	Formula	C₂₅H₃₁ClF₂O₅
CAS No.	66852-54-8	SDF	Download Halobetasol Propionate SDF
Smiles	CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)CCl
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 97 mg/mL ( (200.01 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 38 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):